Biosimilars

Filter

Current filters:

None

Popular Filters

1 to 25 of 160 results

Japan Pharma outlook 2015

Japan Pharma outlook 2015

06-03-2015

The new pricing system adopted in Japan from April 2014 is a game changer initiative. It pains most of…

BiosimilarsGenericsJapanMarkets & MarketingPricing

US biosimilar approvals poised to grow, but market uptake faces challenges, says Tufts CSDD

05-03-2015

Biosimilar approvals in the USA are expected to increase during the next five years, but safety concerns…

BiosimilarsBiotechnologyFinancialMarkets & MarketingRegulationUSA

European generics group launches Code of Conduct

05-03-2015

Following the adoption of the European Commission Guiding Principles Promoting Good Governance in the…

BiosimilarsEuropeGenericsMarkets & MarketingRegulation

Biosimilars viable only for biologics with sales of $898 million, says Prime Therapeutics report

Biosimilars viable only for biologics with sales of $898 million, says Prime Therapeutics report

26-02-2015

Although there is widespread optimism around the first biosimilars being launched in the USA, a new report…

BiosimilarsProductionRegulationUnited StatesUSA

Biobetters plugging gap in the biosimilar market for growth hormone deficiency

Biobetters plugging gap in the biosimilar market for growth hormone deficiency

25-02-2015

Although there appears to be a gap in the market for biosimilars in growth hormone deficiency indications,…

BiosimilarsGeneticsGlobalDataPricingProduction

Intas becomes first Indian company to launch biosimilar in the EU

Intas becomes first Indian company to launch biosimilar in the EU

23-02-2015

Indian biopharma company Intas has become the first Indian company to launch a biosimilar in highly regulated…

BiosimilarsBiotechnologyFilgrastimHematologyImmunologicalsIndiaIntas PharmaceuticalsMarkets & MarketingRegulation

Russia’s Biocad to invest $120 million in expansion of domestic operations

23-02-2015

Biocad, one of Russia’s largest biotech companies, has officially announced its plans to invest up…

AvastinBiocadBiosimilarsBiotechnologyFinancialHerceptinOncologyProductionRocheRussia

Roche likely to lose another state contract in Russia

Roche likely to lose another state contract in Russia

23-02-2015

Swiss pharma giant Roche will probably lose one of its major contracts in Russia for the next several…

AvastinBiocadBiosimilarsBiotechnologyMarkets & MarketingOncologyRocheRussia

Opportunities, challenges, strategies and forecasts for generic drugs market; report

Opportunities, challenges, strategies and forecasts for generic drugs market; report

23-02-2015

Already prevalent in the USA, Europe and much of the developing world, generic drugs are now finding…

BiosimilarsEuropeGenericsGlobalMarkets & Marketing

Hospira’s biosimilar Inflectra comparable to Remicade in IBD treatment

Hospira’s biosimilar Inflectra comparable to Remicade in IBD treatment

19-02-2015

Positive data have been presented today on the use of Hospira's Inflectra (infliximab), the world's first…

BiosimilarsBiotechnologyGastro-intestinalsHospiraInflectraJohnson & JohnsonMerck & CoRemicadeResearch

Pfenex soars on Lucentis biosimilar deal with Hospira

Pfenex soars on Lucentis biosimilar deal with Hospira

10-02-2015

Shares of US clinical-stage biotech firm Pfenex leapt 28% to $8.85 in morning trading, after the company…

BiosimilarsBiotechnologyGenentechGlobalHospiraLicensingLucentisNovartisOphthalmicsPF582PfenexResearchRoche

GlobalData analyst views implications of Pfizer’s acquisition of Hospira

07-02-2015

Just days after gaining US Food and Drug Administration breakthrough approval for Ibrance (palbociclib)…

BiosimilarsHospiraMergers & AcquisitionsPfizerPharmaceutical

UPDATE: Pfizer to acquire Hospira for around $17 billion

UPDATE: Pfizer to acquire Hospira for around $17 billion

05-02-2015

US pharma giant Pfizer has entered into a definitive merger agreement to acquire Hospira, news of which…

BiosimilarsGenericsHospiraMergers & AcquisitionsPfizer

Amgen reports its biosimilar ABP 501 meets primary endpoint against adalimumab

Amgen reports its biosimilar ABP 501 meets primary endpoint against adalimumab

04-02-2015

USA-based biotech major Amgen has reported positive top-line data from a Phase III study of its biosimilar…

ABP 501adalimumabAmgenAnti-Arthritics/RheumaticsBiosimilarsHumiraResearchUSA

CMOs must offer meaningful value to take advantage of biosimilars trend, says report

30-01-2015

If contract manufacturing organizations are to take advantage of the wave of interest in biosimilars,…

BiosimilarsBiotechnologyComputer hardwareLicensingPharmSourceProduction

Repligen appoints Tony Hunt as chief executive officer

Repligen appoints Tony Hunt as chief executive officer

21-01-2015

Biologics specialist Repligen has appointed Tony Hunt as the company’s next chief executive officer.

BiosimilarsBoardroomLife TechnologiesRepligenTony Hunt

Naming conventions for biosimilars in Australia

Naming conventions for biosimilars in Australia

21-01-2015

Following recent international developments in the area of biosimilar naming, Australian regulator the…

AustraliaBiosimilarsBiotechnologyRegulationTherapeutic Goods Administration

New phase of MAb biosimilars opportunities in Japan

New phase of MAb biosimilars opportunities in Japan

21-01-2015

The launch of Remicade (infliximab, from Johnson & Johnson) biosimilar in December 2014 in the Japan…

BiosimilarserythropoietinGenericsJapanMarkets & MarketingRegulationRemicade

Hospira submits new BLA for epoetin alfa biosimilar In USA

12-01-2015

US injectable drugs and infusion technologies and biosimilars developer Hospira has submitted a Biologics…

AmgenBiosimilarsBiotechnologyepoetinEpogenHematologyHospiraJanssenJohnson & JohnsonProcritRegulationRetacritUSA

BIO urges US FDA to release guidance on biosimilars

BIO urges US FDA to release guidance on biosimilars

08-01-2015

The US trade group the Biotechnology Industry Organization (BIO) has called on the Food and Drug Administration…

BiosimilarsBiotechnologyRegulationUSA

Sandoz’ Neupogen biosimilar backed by FDA advisory panel

Sandoz’ Neupogen biosimilar backed by FDA advisory panel

08-01-2015

The US Food and Drug Administration Oncologic Drugs Advisory Committee (ODAC), in a unanimous vote, recommended…

AmgenBiosimilarsBiotechnologyFilgrastimNeupogenNovartisOncologyRegulationSandozUSAZarxio

1 to 25 of 160 results

COMPANY SPOTLIGHT

Menarini

Back to top